Dopamine D
Dopamine D(1) receptor
Functional selectivity
Neurophysiology
β-arrestin
Journal
The international journal of biochemistry & cell biology
ISSN: 1878-5875
Titre abrégé: Int J Biochem Cell Biol
Pays: Netherlands
ID NLM: 9508482
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
12
07
2021
revised:
16
02
2022
accepted:
03
06
2022
pubmed:
11
6
2022
medline:
29
6
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
The awareness of the potential importance of functional selectivity/biased signaling has led to the discovery of biased compounds as both research tools and novel drugs. A major pan-receptor focus has been to identify GPCR-selective ligands that have bias in G protein-dependent vs. β-arrestin related signaling. Although this field has exploded during the past two decades, it is only recently that highly β-arrestin biased ligands for the dopamine D
Identifiants
pubmed: 35688404
pii: S1357-2725(22)00080-2
doi: 10.1016/j.biocel.2022.106235
pmc: PMC10266066
mid: NIHMS1904596
pii:
doi:
Substances chimiques
Arrestins
0
Ligands
0
beta-Arrestin 1
0
beta-Arrestins
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106235Subventions
Organisme : NINDS NIH HHS
ID : R01 NS105471
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG071675
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
Eur J Pharmacol. 1978 Aug 15;50(4):419-30
pubmed: 568069
Nat Rev Drug Discov. 2013 Mar;12(3):205-16
pubmed: 23411724
Mol Pharmacol. 1998 Sep;54(3):453-8
pubmed: 9730903
Neuropsychopharmacology. 2018 Apr;43(5):1164-1173
pubmed: 29068002
Nat Commun. 2018 Feb 14;9(1):674
pubmed: 29445200
Mol Pharmacol. 2005 Oct;68(4):1039-48
pubmed: 15985612
Br J Pharmacol. 2014 Nov;171(21):4797-807
pubmed: 24641481
J Pharmacol Exp Ther. 2002 Jun;301(3):1179-89
pubmed: 12023553
J Biol Chem. 2004 Sep 17;279(38):39317-30
pubmed: 15247297
Eur J Pharmacol. 1978 Sep 1;51(1):19-28
pubmed: 29762
J Pharmacol Exp Ther. 2002 Jun;301(3):1166-78
pubmed: 12023552
Nature. 1998 Dec 3;396(6710):474-7
pubmed: 9853756
Mol Pharmacol. 2015 Aug;88(2):368-79
pubmed: 26044547
J Parkinsons Dis. 2020;10(4):1515-1527
pubmed: 32986682
Sci Signal. 2018 Oct 16;11(552):
pubmed: 30327411
J Pharmacol Exp Ther. 1998 Jul;286(1):345-53
pubmed: 9655879
Sci Signal. 2016 Apr 19;9(424):ra39
pubmed: 27095593
ACS Chem Neurosci. 2015 Aug 19;6(8):1411-9
pubmed: 25891774
Neuropsychopharmacology. 2011 Feb;36(3):551-8
pubmed: 20980993
Science. 2005 Apr 22;308(5721):512-7
pubmed: 15845844
Mol Psychiatry. 2021 Feb;26(2):645-655
pubmed: 30532019
J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
pubmed: 16803859
J Neurosci. 2002 Oct 15;22(20):8911-21
pubmed: 12388598
Eur J Pharmacol. 1989 Jul 4;166(1):111-3
pubmed: 2572425
J Biol Chem. 2012 Aug 10;287(33):27806-12
pubmed: 22753408
Neuropharmacology. 2019 May 15;150:46-58
pubmed: 30858103
Hypertension. 2015 Apr;65(4):834-40
pubmed: 25712721
Biol Psychiatry. 2015 Dec 15;78(12):860-70
pubmed: 25731884